Liraglutide Injection Shortage

• • Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00169-4060-12
  • Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00169-4060-13

• • Meitheal launched liraglutide injection in April 2025.
  • Novo Nordisk has Victoza on shortage due to manufacturing delays.
  • Novo Nordisk has Saxenda available.
  • Teva launched the authorized generic of liraglutide in late-June 2024.

• • Saxenda subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 5 count, NDC 00169-2800-15
  • Liraglutide subcutaneous injection, Meitheal Pharmaceuticals, 6 mg/mL, 3 mL pen injector, 2 count, NDC 71288-0563-85
  • Liraglutide subcutaneous injection, Meitheal Pharmaceuticals, 6 mg/mL, 3 mL pen injector, 3 count, NDC 71288-0563-84
  • Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00480-3667-20
  • Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00480-3667-22

Estimated Resupply Dates

• • Novo Nordisk has Victoza 6 mg/mL 3 mL pens in 2 and 3 count presentations on intermittent back order and the company is releasing supplies as they become available.